Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12077907 | 0.98 | PNMT (0.46) | PNMTASIC3HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL30062686 | 0.98 | PNMT (0.46) | PNMTASIC3HTR2CHTR2BHTR2A | |
| SCHEMBL29757608 | 0.92 | PNMT (0.52) | PNMTASIC3HTR2BCD44MAOB | |
| SCHEMBL12691564 | 0.92 | PNMT (0.52) | PNMTASIC3HTR2BCD44MAOB | |
| Hydrochloric Acid SCHEMBL12540879 | 0.91 | PNMT (0.50) | PNMTASIC3CD44MAOBDRD2 | |
| SCHEMBL29971347 | 0.84 | CHRNB2 (0.42) | PNMTCHRNB2CHRNA4 | |
| SCHEMBL903474 | 0.84 | CHRNB2 (0.42) | PNMTCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL20379721 | 0.82 | CHRNB2 (0.41) | PNMTCHRNB2CHRNA4 | |
| SCHEMBL20038301 | 0.77 | PNMT (0.47) | PNMTASIC3HTR2CHTR2BCD44 | |
| SCHEMBL8264642 | 0.77 | ADCY6 (0.47) | PNMTASIC3HTR2CHTR2BCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| EP-4572761-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| CN-119730854-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024260464-A1 | PI3K INHIBITORS AND USE THEREOF | REGOR PHARMACEUTICALS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4436664-A1 | ANTAGONISTS OF CAV 2.3 | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024069448-A1 | SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-04-04 | — | — | WO | disclosed |
| CN-117658900-A | Preparation method of tetrahydronaphthyridine compound and intermediate thereof | 南京药石科技股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-8623885-B2 | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 | AMGEN INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623885-B2 | Fused tricyclic dual inhibitors of CDK 4/6 and FLT3 | AMGEN INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440652-B2 | MST1 kinase inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2012129344-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120244110-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244110-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012121992-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001876-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE7A | PNMT 1421/4885ASIC3 2737/4885HTR2C 655/4885 |
| US-20120244110-A1 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 | CDK6, CDKL4, CDK16 | PNMT 3940/4885ASIC3 4348/4885HTR2C 4194/4885 |
| US-20120225857-A1 | MST1 KINASE INHIBITORS AND METHODS OF THEIR USE | MST1, STK10, STK3 | PNMT 3315/4885ASIC3 3744/4885HTR2C 4793/4885 |
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | CACNA1E, CACNA1A, CACNA1S | PNMT 3789/4885ASIC3 264/4885HTR2C 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.